使用存档与新采集肿瘤样本评估PD-L1表达及总生存:KEYNOTE-010试验的更新分析
KEYNOTE-010更新分析显示,在PD-L1阳性晚期非小细胞肺癌(NSCLC)中,帕博利珠单抗较多西他赛持续改善总生存(OS),总人群HR 0.66(95%CI 0.57, 0.77)。预设探索性分析按存档样本(455例)与新采集样本(578例)分层,两亚组OS获益均持续存在,存档样本TPS≥50%的OS HR 0.64(95%CI 0.45, 0.91),新采集样本TPS≥50%的OS HR 0.40(95%CI 0.28, 0.56)。
要点
- 帕博利珠单抗较多西他赛持续改善PD-L1阳性晚期NSCLC的OS,总HR 0.66(95%CI 0.57, 0.77)。
- TPS≥50%时,存档样本OS HR 0.64(95%CI 0.45, 0.91),新采集样本OS HR 0.40(95%CI 0.28, 0.56)。
- TPS≥1%时,存档样本OS HR 0.74(95%CI 0.59, 0.93),新采集样本OS HR 0.59(95%CI 0.48, 0.73)。
核心结论
- 帕博利珠单抗较多西他赛在意向治疗人群及新采集和存档样本亚组中持续改善OS。
研究设计与样本
- KEYNOTE-010为预设探索性分析,比较基于存档与新采集肿瘤样本PD-L1表达的结果,使用近期更新的生存数据。
- PD-L1由中心实验室采用免疫组化(22C3抗体)在存档或新采集肿瘤样本中评估。
- 患者接受帕博利珠单抗2或10 mg/kg每3周一次或多数西他赛75 mg/m2每3周一次,治疗24个月或直至进展/不可耐受毒性/其他原因。
- 疗效由RECIST v1.1每9周评估,生存每2个月评估;主要终点为TPS≥50%和≥1%人群的OS和PFS,本分析中帕博利珠单抗剂量合并。
- 共分析1033例患者,其中455例(44%)基于存档样本入组,578例(56%)基于新采集肿瘤样本入组。
主要发现
- 数据截止2017年3月24日,中位随访31个月(范围23-41),较主要分析额外随访18个月。
- 帕博利珠单抗较多西他赛持续改善既往治疗、PD-L1表达的晚期NSCLC患者OS,HR 0.66(95%CI 0.57, 0.77)。
- 存档样本约40%、新采集样本约45%为PD-L1 TPS≥50%。
- TPS≥50%时,存档样本OS HR 0.64(95%CI 0.45, 0.91),新采集样本OS HR 0.40(95%CI 0.28, 0.56)。
- TPS≥1%时,存档样本OS HR 0.74(95%CI 0.59, 0.93),新采集样本OS HR 0.59(95%CI 0.48, 0.73);TPS≥50%时PFS HR存档0.63(95%CI 0.45, 0.89)与新采集0.53(95%CI 0.38, 0.72)相似,TPS≥1%时PFS HR存档0.82(95%CI 0.66, 1.02)与新采集0.83(95%CI 0.68, 1.02)相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC). A prespecified exploratory analysis compared outcomes in patients based on PD-L1 expression in archival versus newly collected tumor samples using recently updated survival data. PATIENTS AND METHODS: PD-L1 was assessed centrally by immunohistochemistry (22C3 antibody) in archival or newly collected tumor samples. Patients received pembrolizumab 2 or 10 mg/kg Q3W or docetaxel 75 mg/m2 Q3W for 24 months or until progression/intolerable toxicity/other reason. Response was assessed by RECIST v1.1 every 9 weeks, survival every 2 months. Primary end points were OS and progression-free survival (PFS) in tumor proportion score (TPS) ≥50% and ≥1%; pembrolizumab doses were pooled in this analysis. RESULTS: At date cut-off of 24 March 2017, median follow-up was 31 months (range 23-41) representing 18 additional months of follow-up from the primary analysis. Pembrolizumab versus docetaxel continued to improve OS in patients with previously treated, PD-L1-expressing advanced NSCLC; hazard ratio (HR) was 0.66 [95% confidence interval (CI): 0.57, 0.77]. Of 1033 patients analyzed, 455(44%) were enrolled based on archival samples and 578 (56%) on newly collected tumor samples. Approximately 40% of archival samples and 45% of newly collected tumor samples were PD-L1 TPS ≥50%. For TPS ≥50%, the OS HRs were 0.64 (95% CI: 0.45, 0.91) and 0.40 (95% CI: 0.28, 0.56) for archival and newly collected samples, respectively. In patients with TPS ≥1%, OS HRs were 0.74 (95% CI: 0.59, 0.93) and 0.59 (95% CI: 0.48, 0.73) for archival and newly collected samples, respectively. In TPS ≥50%, PFS HRs were similar across archival [0.63 (95% CI: 0.45, 0.89)] and newly collected samples [0.53 (95% CI: 0.38, 0.72)]. In patients with TPS ≥1%, PFS HRs were similar across archival [0.82 (95% CI: 0.66, 1.02)] and newly collected samples [0.83 (95% CI: 0.68, 1.02)]. CONCLUSION: Pembrolizumab continued to improve OS over docetaxel in intention to treat population and in subsets of patients with newly collected and archival samples. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01905657.
引用
- Herbst RS, Baas P, Perez-Gracia JL, et al. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Ann Oncol. 2019. PMID: 30657853. doi:10.1093/annonc/mdy545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。